TRACON Pharmaceuticals, Inc. (TCON): Future Price to Earnings
The expected P/E multiple for TRACON Pharmaceuticals (TCON) reflects the impact of management's strategy regarding asset liquidation and the transparent winding down of operations. The value remains at 0.00, driven by the role of TRACON Pharmaceuticals (TCON) as an expert partner in clinical trials. This model helps biotech startups bring oncology drugs to market faster, filling the gap in effective therapy methods through collaboration with pharma behemoths.
TRACON Pharmaceuticals - analytical breakdowns and key metrics (TCON)
- stock quotes and analyst forecast:
- stock exchange capitalization data:
- balance sheet equity data:
- debt level and financial liquidity data:
Debt to Equity TRACON Pharmaceuticals|TCON - Long-Term Liabilities to Equity|Short-Term Debt to Capital TRACON Pharmaceuticals, Inc.|TCON - Aggregate Debt Obligations|Debts to Book Capitalization TRACON|TCON - Company Long-Term Debts|Company Short-Term Debt TRACON Pharmaceuticals|Quick Liquidity traconpharma.com
- company profitability and valuation multiples indicators:
TCON - Net Income|Projected Future Earnings TRACON Pharmaceuticals|TCON - P/E Multiple|Forward P/E Multiple traconpharma.com|TCON - Price/Earnings to Growth Multiple|EV/EBITDA Multiple TRACON Pharmaceuticals Inc.|TCON - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months TRACON Pharmaceuticals|TCON - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months traconpharma.com|TCON - Net earnings per one share growth for the current year|Earnings growth forecast for next year TRACON Pharmaceuticals
- sales revenue and business income indicators:
Fundamental valuation:TRACON Pharmaceuticals Inc.
For TRACON Pharmaceuticals, a leader in the development of targeted oncology drugs, the company's forward P/E ratio of 0.00 serves as an indicator of market expectations regarding the efficacy of clinical trials. This ratio is calculated by dividing the current share price by the projected annual net profit, allowing investors to determine the extent of the premium paid for future business growth and the risk of a "value trap."
Analysis of competing companies
Projected Price to Earnings TEM (Tempus AI, Inc)|Qiagen Group (QGEN) - Forward Price to Earnings Multiple|Future Price to Earnings ionispharma.com IONS|Market Cap to Projected Earnings Repligen Corporation (RGEN)|RNA: Projected Price to Earnings|Future Price to Earnings Multiple CRSP (CRISPR Therapeutics Corp)|WGS: Forward P/E Multiple|Projected Price to Earnings Ratio Ultragenyx Corp (RARE)|BEAM (Beam Therapeutics Inc) - Forward P/E Multiple|SRPT: Future Price to Earnings Multiple|Future Price to Earnings Twist Bioscience Corp (TWST)|Projected Price to Earnings 10x Genomics Inc TXG|Intellia Therapeutics, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple STOK|BLFS - Future Price to Earnings|Wave Life Sciences (WVE) - Projected Price to Earnings|MAZE: Forward P/E Multiple|Sionna Therapeutics, Inc. (SION) - Forward P/E Multiple|Future Price to Earnings Prime Medicine, Inc.|TSHA (Taysha) - Market Cap to Future Earnings Ratio|Projected Price to Earnings QURE (uniQure Pharma)|Market Cap to Projected Earnings meiragtx.com|Future Price to Earnings REGENXBIO RGNX|SLDB - Projected Price to Earnings|Ocugen, Inc. - Forward P/E Multiple|PACB (Pacific Biosciences of California) - Price to Future Earnings Ratio|BNTC: Forward P/E Multiple|DSGN - Market Cap to Projected Earnings|RCKT (Rocket Pharma) - Forward P/E Multiple|Future Price to Earnings FDMT|Future Price to Earnings Lexeo Therapeutics, Inc. (LXEO)|Korro Bio Inc. - Price to Future Earnings Ratio|editasmedicine.com - Projected Price to Earnings|Market Cap to Projected Earnings silence-therapeutics.com (SLN)|PRQR: Projected Price to Earnings|Projected Price to Earnings Ratio codexis.com|SGMO: Forward P/E Multiple|Projected Price to Earnings Ratio Nautilus Biotechnology Inc (NAUT)|Projected Price to Earnings MGX|DTIL (Precision BioSciences) - Market Cap to Future Earnings Ratio|Future Price to Earnings Generation Bio Corp (GBIO)|Boundless Bio - Price to Future Earnings Ratio|Future Price to Earnings Exicure, Inc. XCUR|Future Price to Earnings Multiple IMNN|PHIO - Future Price to Earnings|Market Cap to Projected Earnings Mustang Bio Inc MBIO|RNAZ: Forward P/E Multiple|Price to Future Earnings Ratio BNGO|APDN (Applied DNA Sciences Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Bluebird Bio BLUE|Forward P/E Multiple IPA|Omega Therapeutics (OMGA) - Forward Price to Earnings Multiple|Forward P/E Multiple OMIC (Singular Genomics Systems Inc)|Forward Price to Earnings Multiple Regulus Therapeutics Inc|SYRS - Future Price to Earnings|Future Price to Earnings Multiple TBIO (Codex DNA)|UBX: Forward P/E Multiple
